TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Daily Photo Galleries

Wednesday, June 4, 2014, 10:51 a.m.
 

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 


Show commenting policy

Most-Read Business Headlines

  1. Home appraisal is below sales price — now what?
  2. If you get this letter from the IRS, it’s legitimate
  3. Venting online about job protected
  4. Corporate missteps hurt reputations, profits, sometimes in long run
  5. Tourists rush to visit Cuba before American influence felt
  6. Komando: Boost cellphone signal when nixing landline
  7. France plane crash victim’s father calls for airlines to focus on pilot welfare
  8. Farmers fund research on gluten-free wheat
  9. Stop foreign dumping, U.S. Steel CEO Longhi tells Congress
  10. Heinz merging with Kraft in mega-deal; headquarters to stay in Pittsburgh
  11. Falling demand for steel not likely to reverse any time soon